Everpar Advisors LLC Purchases Shares of 3,012 Gilead Sciences, Inc. $GILD

Key Points

• Everpar Advisors LLC has acquired a new stake in Gilead Sciences, purchasing 3,012 shares valued at approximately $334,000.
• Several analysts have recently upgraded Gilead Sciences' stock ratings, with target prices ranging from $127.00 to $145.00, indicating positive outlooks for the company's performance.
• Gilead Sciences has announced a quarterly dividend of $0.79 per share, representing a 2.9% dividend yield, with the payout scheduled for September 29th.

Everpar Advisors LLC bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 3,012 shares of the biopharmaceutical company's stock, valued at approximately $334,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Ariel Investments LLC grew its position in Gilead Sciences by 7.7% in the first quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company's stock worth $48,229,000 after acquiring an additional 30,630 shares in the last quarter. Golden State Wealth Management LLC grew its position in Gilead Sciences by 14.5% in the first quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock worth $97,000 after acquiring an additional 109 shares in the last quarter. Swedbank AB grew its position in Gilead Sciences by 0.8% in the first quarter. Swedbank AB now owns 2,118,632 shares of the biopharmaceutical company's stock worth $237,393,000 after acquiring an additional 16,663 shares in the last quarter. Focus Partners Wealth grew its position in Gilead Sciences by 21.2% in the first quarter. Focus Partners Wealth now owns 142,666 shares of the biopharmaceutical company's stock worth $15,986,000 after acquiring an additional 24,930 shares in the last quarter. Finally, ASR Vermogensbeheer N.V. purchased a new position in Gilead Sciences in the first quarter worth $11,688,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Up 0.4%

Shares of NASDAQ GILD traded up $0.47 on Friday, reaching $114.09. 12,580,487 shares of the company's stock traded hands, compared to its average volume of 5,841,828. Gilead Sciences, Inc. has a 12 month low of $81.83 and a 12 month high of $121.83. The business's 50 day simple moving average is $114.10 and its two-hundred day simple moving average is $110.03. The company has a market cap of $141.56 billion, a price-to-earnings ratio of 22.73, a price-to-earnings-growth ratio of 0.77 and a beta of 0.36. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same quarter last year, the firm earned $2.01 earnings per share. The business's revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be given a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.8%. Gilead Sciences's dividend payout ratio is 62.95%.

Insiders Place Their Bets

In related news, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the sale, the insider owned 114,168 shares in the company, valued at approximately $13,532,333.04. This trade represents a 19.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the completion of the sale, the chief executive officer owned 595,725 shares in the company, valued at $67,692,231.75. This represents a 1.65% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 82,000 shares of company stock valued at $9,390,030. Insiders own 0.27% of the company's stock.

Analyst Upgrades and Downgrades

GILD has been the subject of several analyst reports. Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target for the company in a research report on Friday, July 25th. Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $135.00 to $145.00 and gave the company an "overweight" rating in a research report on Tuesday, September 16th. Truist Financial upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and upped their price target for the company from $108.00 to $127.00 in a research report on Friday, August 8th. Finally, UBS Group upped their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research report on Friday, August 8th. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $117.17.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.